In the latest session, CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $57.96 down -1.29% from its previous closing price of $58.72. On the day, 1176528 shares were traded.
Ratios:
For a deeper understanding of CRISPR Therapeutics AG’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.54 and its Current Ratio is at 17.54. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
On December 11, 2023, TD Cowen Downgraded its rating to Underperform which previously was Market Perform but kept the price unchanged to $30.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 15 ’24 when Kulkarni Samarth sold 20,000 shares for $72.48 per share. The transaction valued at 1,449,628 led to the insider holds 208,122 shares of the business.
Prasad Raju sold 3,524 shares of CRSP for $256,160 on Mar 15 ’24. The Chief Financial Officer now owns 6,476 shares after completing the transaction at $72.69 per share. On Mar 12 ’24, another insider, Kulkarni Samarth, who serves as the Chief Executive Officer of the company, sold 4,583 shares for $74.44 each. As a result, the insider received 341,159 and left with 208,122 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 13.25 while its Price-to-Book (P/B) ratio in mrq is 2.46.
Stock Price History:
Over the past 52 weeks, CRSP has reached a high of $91.10, while it has fallen to a 52-week low of $37.55.
Shares Statistics:
A total of 84.88M shares are outstanding, with a floating share count of 80.46M. Insiders hold about 5.21% of the company’s shares, while institutions hold 66.20% stake in the company.
Earnings Estimates
There are 17 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$1.42 for the current quarter, with a high estimate of $0.74 and a low estimate of -$1.84, while EPS last year was -$0.67. The consensus estimate for the next quarter is -$1.53, with high estimates of -$1.02 and low estimates of -$1.86.
Analysts are recommending an EPS of between -$2.63 and -$7.48 for the fiscal current year, implying an average EPS of -$5.68. EPS for the following year is -$4.27, with 20 analysts recommending between $5.08 and -$7.95.
Revenue Estimates
A total of 16 analysts believe the company’s revenue will be $17.2M this quarter.It ranges from a high estimate of $200M to a low estimate of –$. As of the current estimate, CRISPR Therapeutics AG’s year-ago sales were $100M, an estimated decrease of -82.80% from the year-ago figure. For the next quarter, 16 analysts are estimating revenue of $10.05M, a decrease of -85.60% less than the figure of -$82.80% in the same quarter last year. There is a high estimate of $43.7M for the next quarter, whereas the lowest estimate is –$.
A total of 22 analysts have provided revenue estimates for CRSP’s current fiscal year. The highest revenue estimate was $457.9M, while the lowest revenue estimate was $15M, resulting in an average revenue estimate of $109.13M. In the same quarter a year ago, actual revenue was $371.21M, down -70.60% from the average estimate. Based on 22 analysts’ estimates, the company’s revenue will be $409.41M in the next fiscal year. The high estimate is $3.31B and the low estimate is $40M. The average revenue growth estimate for next year is up 275.20% from the average revenue estimate for this year.
